Every second counts
Kiniksa Pharmaceuticals (kiniksa.com) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 48th percentile of 8518 Healthcare brands.
Kiniksa Pharmaceuticals is a biopharmaceutical company headquartered in Lexington, United States, founded in 2015. It develops innovative therapies, including investigational monoclonal antibodies, targeting serious and debilitating diseases such as recurrent pericarditis. The company emphasizes rapid clinical progress and a patient-centric approach, positioning itself as a global innovator committed to accelerating treatment options for patients, healthcare providers, and clinical trial participants.
| Brand Name | Kiniksa Pharmaceuticals |
|---|---|
| Domain | kiniksa.com |
| Industry | Healthcare |
| Founded | 2015 |
| Headquarters | Lexington, United States |
| Main Competitors | Sobi (Swedish Orphan Biovitrum) (89/100), Regeneron Pharmaceuticals (92/100), Novartis (75/100), Horizon Therapeutics (80/100), Roche (82/100) |
Moz Domain Authority 37/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #1,535,535 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Kiniksa Pharmaceuticals is a biopharmaceutical company that believes every second makes a difference for patients living with debilitating diseases." (Meta description: 19 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Product/Article schema, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx, Drupal.
Social footprint: verified profiles on LinkedIn, Instagram, X (Twitter); no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Kiniksa Pharmaceuticals?", Claude could identify the brand as of August 2026. Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for diseases with significant unmet medical need, particularly in immuno-inflammatory conditions and cardiovascular disease. Its lead product, ARCALYST (rilonacept), is appr Best known for developing ARCALYST (rilonacept) for recurrent pericarditis.
When asked "Best brands similar to Kiniksa Pharmaceuticals?", Claude would recommend Kiniksa Pharmaceuticals as of August 2026. It's a notable player in the immuno-inflammatory biopharma space with an approved product, so it would come up in discussions of companies targeting rare inflammatory and cardiovascular conditions.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Kiniksa Pharmaceuticals's main competitors in Healthcare: Sobi (Swedish Orphan Biovitrum) (89/100), Regeneron Pharmaceuticals (92/100), Novartis (75/100), Horizon Therapeutics (80/100), Roche (82/100).
Sources: Brand Analyzer scan
Kiniksa Pharmaceuticals has limited AI-search visibility, scoring 35/100 on Brand Analyzer's AI visibility composite (visibility 19, trust 38, recommendation 59). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Kiniksa Pharmaceuticals was founded in 2015. Kiniksa Pharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Kiniksa Pharmaceuticals scores 59/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Kiniksa Pharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Kiniksa Pharmaceuticals is a biopharmaceutical company headquartered in Lexington, United States, founded in 2015. It focuses on developing therapies for patients with debilitating and serious diseases, with an emphasis on rapid clinical development and patient-centric urgency.
Kiniksa Pharmaceuticals scores 35/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Kiniksa Pharmaceuticals has a weak AI-visibility profile at 35/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (59/100) and its weakest is visibility (19/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,535,535 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 37/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Kiniksa Pharmaceuticals from memory (August 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Kiniksa Pharmaceuticals: KidsAbility (76/100), Kester (76/100), INDIBA (76/100), Kokilaben Hospital (76/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), ZOLL Data Systems (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.